메뉴 건너뛰기




Volumn 14, Issue 5, 2013, Pages 592-595

A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ros1 gene rearrangements

Author keywords

Chemotherapy; Molecular subtypes; NSCLC; Pemetrexed; ROS1

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CRIZOTINIB; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE; ROS1 PROTEIN; UNCLASSIFIED DRUG;

EID: 84883816641     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.04.008     Document Type: Article
Times cited : (33)

References (12)
  • 1
    • 36849065315 scopus 로고    scopus 로고
    • Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
    • K. Rikova, A. Guo, and Q. Zeng Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
    • (2007) Cell , vol.131 , pp. 1190-1203
    • Rikova, K.1    Guo, A.2    Zeng, Q.3
  • 2
    • 84865441368 scopus 로고    scopus 로고
    • Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
    • K.D. Davies, A.T. Le, and M.F. Theodoro Identifying and targeting ROS1 gene fusions in non-small cell lung cancer Clin Cancer Res 18 2012 4570 4579
    • (2012) Clin Cancer Res , vol.18 , pp. 4570-4579
    • Davies, K.D.1    Le, A.T.2    Theodoro, M.F.3
  • 3
    • 84863338079 scopus 로고    scopus 로고
    • ROS1 rearrangements define a unique molecular class of lung cancers
    • K. Bergethon, A.T. Shaw, and S.H. Ou ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 2012 863 870
    • (2012) J Clin Oncol , vol.30 , pp. 863-870
    • Bergethon, K.1    Shaw, A.T.2    Ou, S.H.3
  • 4
    • 84865092224 scopus 로고    scopus 로고
    • Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement
    • (abstract 7508)
    • A.T. Shaw, D.R. Camidge, J.A. Engelman, and B.J. Solomon Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement J Clin Oncol 30 suppl 2012 (abstract 7508)
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Shaw, A.T.1    Camidge, D.R.2    Engelman, J.A.3    Solomon, B.J.4
  • 5
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 6
    • 84857507055 scopus 로고    scopus 로고
    • Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial
    • L. Paz-Ares, F. de Marinis, and M. Dediu Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol 13 2012 247 255
    • (2012) Lancet Oncol , vol.13 , pp. 247-255
    • Paz-Ares, L.1    De Marinis, F.2    Dediu, M.3
  • 7
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
    • (2004) J Clin Oncol , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3
  • 8
    • 64049115311 scopus 로고    scopus 로고
    • The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies
    • G. Scagliotti, N. Hanna, and F. Fossella The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies Oncologist 14 2009 253 263
    • (2009) Oncologist , vol.14 , pp. 253-263
    • Scagliotti, G.1    Hanna, N.2    Fossella, F.3
  • 9
    • 79953029071 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
    • D.R. Camidge, S.A. Kono, and X. Lu Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed J Thorac Oncol 6 2011 774 780
    • (2011) J Thorac Oncol , vol.6 , pp. 774-780
    • Camidge, D.R.1    Kono, S.A.2    Lu, X.3
  • 10
    • 80052261903 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase translocation: A predictive biomarker of pemetrexed in patients with non-small cell lung cancer
    • J.O. Lee, T.M. Kim, and S.H. Lee Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer J Thorac Oncol 6 2011 1474 1480
    • (2011) J Thorac Oncol , vol.6 , pp. 1474-1480
    • Lee, J.O.1    Kim, T.M.2    Lee, S.H.3
  • 11
    • 84876415170 scopus 로고    scopus 로고
    • Thymidylate synthase (TS) gene expression in patients with ALK positive (+) non-small cell lung cancer (NSCLC): Implications for therapy
    • (abstract 7582)
    • DR. Gandara, E. Huang, and S. Desai Thymidylate synthase (TS) gene expression in patients with ALK positive (+) non-small cell lung cancer (NSCLC): implications for therapy J Clin Oncol 30 suppl 2012 (abstract 7582)
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Gandara, D.R.1    Huang, E.2    Desai, S.3
  • 12
    • 84876507123 scopus 로고    scopus 로고
    • Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    • A.T. Shaw, A.M. Varghese, and B.J. Solomon Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer Ann Oncol 24 2013 59 66
    • (2013) Ann Oncol , vol.24 , pp. 59-66
    • Shaw, A.T.1    Varghese, A.M.2    Solomon, B.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.